These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26924193)

  • 1. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
    Liu IH; Ford JM; Kunz PL
    Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
    Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
    Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
    Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
    Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
    Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
    Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
    Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
    Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
    Li Z; Zhang H; Yang J; Hao T; Li S
    Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
    Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
    Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a new application of the comet assay to assess levels of O6-methylguanine in genomic DNA (CoMeth).
    Ramos AA; Pedro DF; Lima CF; Collins AR; Pereira-Wilson C
    Free Radic Biol Med; 2013 Jul; 60():41-8. PubMed ID: 23391575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
    Oliver JA; Ortiz R; Jimenez-Luna C; Cabeza L; Perazzoli G; Caba O; Mesas C; Melguizo C; Prados J
    J Biosci; 2020; 45():. PubMed ID: 33097678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
    Kaina B; Christmann M; Naumann S; Roos WP
    DNA Repair (Amst); 2007 Aug; 6(8):1079-99. PubMed ID: 17485253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT and PTEN as potential prognostic markers in breast cancer.
    Neto JC; Ikoma MM; Carvalho KC; Vassallo J; De Brot M; Gobbi H; Soares FA; Rocha RM
    Exp Mol Pathol; 2012 Feb; 92(1):20-6. PubMed ID: 22019339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.